Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.

Molecular cancer therapeutics - 1 Sept 2021

Zhang Di, Hou Zhilin, Aldrich Kelly E, Lockwood Lizbeth, Odom Aaron L, Liby Karen T

Abstract excerpt

The nuclear factor erythroid-2-related factor 2 (Nrf2)-Keap1-ARE pathway, a master regulator of oxidative stress, has emerged as a promising target for cancer therapy. Mutations in NFE2L2, KEAP1, and related genes have been found in many human cancers, especially lung cancer. These mutations lead to constitutive activation of the Nrf2 pathway, which promotes proliferation of cancer cells and their resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antioxidants
Share to Kelch-Like ECH-Associated Protein 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Molecular Targeted Therapy

Share to NF-E2-Related Factor 2

Share to Reactive Oxygen Species

Share to Small Molecule Libraries

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34158350
DOI: 10.1158/1535-7163.MCT-21-0210
PMCID: PMC9936621

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.PMID 34158350Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activationSemantic proximity Read ↗

RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.Semantic proximity Read ↗

MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i> -mutant non-small cell lung cancer through covalent inhibition of KEAP1Semantic proximity Read ↗

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisSemantic proximity Read ↗

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activationSemantic proximity Read ↗

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Semantic proximity Read ↗

The involvement of NRF2 in lung cancer.Semantic proximity Read ↗

Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.Semantic proximity Read ↗

Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.Semantic proximity Read ↗

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.